Pulse Biosciences, Inc (PLSE): Price and Financial Metrics
GET POWR RATINGS... FREE!
PLSE Stock Price Chart Interactive Chart >
PLSE Price/Volume Stats
|Current price||$22.15||52-week high||$45.82|
|Prev. close||$22.49||52-week low||$11.40|
|Day high||$22.64||Avg. volume||109,862|
|50-day MA||$22.25||Dividend yield||N/A|
|200-day MA||$23.27||Market Cap||655.77M|
Pulse Biosciences, Inc (PLSE) Company Bio
Pulse Biosciences, a development stage medical device company, focuses on developing medical technologies based on sub-microsecond pulsed electric field technology to detect and treat skin cancer and enhance wound healing. The company was founded in 2014 and is based in Burlingame, California.
Most Popular Stories View All
PLSE Latest News Stream
|Loading, please wait...|
PLSE Latest Social Stream
View Full PLSE Social Stream
Latest PLSE News From Around the Web
Below are the latest news stories about Pulse Biosciences Inc that investors may wish to consider to help them evaluate PLSE as an investment opportunity.
Irreversible Electroporation Ablators Market2021: Business Opportunities, Current Trends, Market Challenges By 2027 | AngioDynamics, Pulse Biosciences
Irreversible Electroporation Ablators Market: Analyst View From 2021-2027 The Global Irreversible Electroporation Ablators Market work provides a concrete market definition along with a detailed structure of industry which helps readers gain a holistic understanding of the research. The study also includes
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company introducing the CellFX® System powered by Nano-Pulse Stimulation (NPS) technology, today announced plans to participate in the upcoming virtual H.C. Wainwright Global Investment Conference. Management is scheduled to participate and hold one-on-one meetings Tuesday, September 14, 2021. A presentation webcast will be available at the start of the conference on Monday, September 13, 20
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation (NPS) technology, today announced the appointment of Mitchell E. Levinson to the newly created role of Chief Strategy Officer, effective immediately, in addition to the continuation of his role as a member of the Pulse Biosciences Board of Directors. As a Board member and medical device industry veteran with a trac
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation (NPS) technology, today announced financial results for the second quarter of 2021. Recent Highlights CellFX System Controlled Launch Program participants totaled 49 at the end of the second quarter, including 34 onboarded during the second quarter across the U.S., Europe and Canada, on track to complete program onb
PLSE Price Returns